Arqit Quantum Inc. is launching an at-the-market offering of up to $125,000,000 of its ordinary shares under a sales agreement with Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC. The shares may be sold from time to time on Nasdaq or through other permitted methods at prevailing market, related or negotiated prices, and the agents will receive up to 3.0% of the gross sales price as compensation.
Arqit plans to use net proceeds for general corporate purposes, including continued product development and commercialization, potential acquisitions and other business opportunities, and repayment of indebtedness. As of September 30, 2025, it had 15,291,767 ordinary shares outstanding, so additional issuances under this program would dilute existing holders.
The company highlights risks that the actual number of shares sold and gross proceeds may be lower than $125.0 million, that investors buying at different times may pay different prices and experience varying dilution, and that future equity or equity-linked financings could further pressure the share price. As a foreign private issuer and emerging growth company, Arqit also benefits from reduced U.S. reporting requirements.
Heritage Assets SCSp, M Management S.A. and Manfredi Lefebvre d'Ovidio filed Amendment No. 6 to their Schedule 13D for Arqit Quantum Inc. (Ordinary Shares, CUSIP G0567U127) to update ownership after dilution and to disclose open-market sales of Business Combination Warrants. The Reporting Persons now beneficially own 10,214,252 Ordinary Shares, representing approximately 46.0% of 22,184,708 outstanding Ordinary Shares (post-Reverse Stock Split basis). The amendment lists multiple warrant sales between August 20 and September 15, 2025, with quantities and average prices disclosed. No other transactions or material changes were reported.
Arqit Quantum Inc. reported the results of its 2025 annual general meeting of shareholders. Holders of 7,483,305 ordinary shares as of the August 8, 2025 record date were represented, which was enough to constitute a quorum. Shareholders approved all proposals presented at the meeting.
They elected directors to serve on the board until the 2028 annual general meeting or until their successors are appointed and qualified. For example, Stephen Chandler received 7,402,283 votes for, 77,029 against, and 3,993 abstentions, while Nicola Barbiero received 6,664,761 votes for, 538,375 against, and 280,169 abstentions.
Form 144 filing for ARQQW (Arqit Quantum Inc. Warrants) reports a proposed sale of 3 common shares through Fidelity Brokerage Services with an approximate aggregate market value of $84.99, listed for sale on 09/03/2025 on NASDAQ. The filing shows 11,545,354 shares outstanding. The shares were acquired on 09/03/2025 under an option originally granted on 01/04/2021, and payment is listed as cash. The filer discloses prior sales by the same person: 6,500 shares sold on 06/23/2025 for $247,182.70 and 238 shares sold on 07/02/2025 for $8,151.83. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
Arqit Quantum Inc. submitted a Form 6-K to provide investors with the notice and proxy materials for its 2025 Annual General Meeting of Shareholders. The meeting is scheduled to be held on September 11, 2025. The filing includes the formal notice of meeting, detailed proxy materials outlining the matters to be voted on, and a form of proxy card shareholders can use to vote their shares.
The report confirms that Arqit files its annual reports under Form 20-F and is signed on behalf of the company by Chief Executive Officer Andrew Leaver. This is a routine corporate governance step to facilitate shareholder participation in the upcoming annual meeting.
Amendment No. 5 to Schedule 13D updates the holdings and recent warrant transactions by Heritage Assets SCSp, M Management S.A. and Manfredi Lefebvre d'Ovidio (the Reporting Persons) in Arqit Quantum Inc. The Reporting Persons now beneficially own 10,273,245 Ordinary Shares, representing approximately 49.6% of the outstanding Ordinary Shares on a post-reverse-split basis. The amendment discloses open-market sales of Business Combination Warrants across multiple dates at average prices ranging from $7.6 to $69.4. It also reports that on August 1, 2025 warrants purchased in September 2024 became exercisable for up to 4,600,000 Ordinary Shares, increasing aggregate reported ownership by over 1%.
Arqit Quantum Inc. (ARQQW) filed a Form 144 disclosing that Patrick Willcocks intends to sell 3,000 common shares through Fidelity Brokerage on or about 21 Jul 2025. The shares were obtained via a stock-option exercise on 13 Feb 2025 and carry an aggregate market value of $150,000. With 11,545,354 shares outstanding, the planned sale equals roughly 0.026 % of the float.
The filing also lists prior insider activity: Willcocks sold 8,373 shares between 23 Jun 2025 and 18 Jul 2025 for total gross proceeds of about $331 k. Adding the proposed sale would raise his 90-day disposals to 11,373 shares, or ≈0.10 % of shares outstanding.
No adverse information about Arqit’s operations is asserted, and the sale appears to be routine liquidity following option exercise. Nonetheless, investors may monitor the continued selling cadence as a sentiment signal.
Form 144 filing details
An affiliate of Arqit Quantum Inc. (symbol: ARQQW) has filed a Form 144 indicating an intention to sell up to 333 common shares through Fidelity Brokerage Services LLC on the NASDAQ exchange. The shares have an aggregate market value of $11,005.72 and represent roughly 0.0029 % of the 11,545,354 shares outstanding.
The seller acquired the shares on 07/01/2025 via restricted-stock vesting received as compensation. No other sales have occurred in the past three months, and the filer certifies that no undisclosed adverse information is known. The approximate sale date listed is 07/07/2025.
Given the small size of the transaction, this notice is unlikely to have a measurable effect on the company’s share price or float. Investors typically view Form 144 filings as neutral routine disclosures unless the volume represents a significant percentage of outstanding shares, which is not the case here.